PURPOSE: To evaluate the rate of presumed endophthalmitis (EO) after intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections performed in an operating room (OR) under sterile conditions in mainland China. METHODS: Retrospective single-center study between September 2012 and December 2017 at Beijing Tongren Eye Center, Beijing, China. Intravitreal injection database was reviewed. All anti-VEGF injections were performed using a standardized sterile technique in an OR. Injection protocols included antibiotics for 3 days pre-injection, topical 5% povidone-iodine rinsing before the procedure, and post-injection antibiotics for 3 days. RESULTS: A total of 37,830 intravitreal injections were performed at Beijing Tongren Eye Center. Three cases were managed as presumed EO (0.0079%). Positive cultures were documented in 2 of 3 cases. EO incidence following ranibizumab and conbercept administration was 0.0088% (3 in 33,930) and 0% (0 in 3,900), respectively. No significant difference was detected between the two drugs (P = 0.745). CONCLUSIONS: Very low EO rates were seen in mainland China using a standardized sterile technique in an OR. However, EO could not be completely avoided.
PURPOSE: To evaluate the rate of presumed endophthalmitis (EO) after intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections performed in an operating room (OR) under sterile conditions in mainland China. METHODS: Retrospective single-center study between September 2012 and December 2017 at Beijing Tongren Eye Center, Beijing, China. Intravitreal injection database was reviewed. All anti-VEGF injections were performed using a standardized sterile technique in an OR. Injection protocols included antibiotics for 3 days pre-injection, topical 5% povidone-iodine rinsing before the procedure, and post-injection antibiotics for 3 days. RESULTS: A total of 37,830 intravitreal injections were performed at Beijing Tongren Eye Center. Three cases were managed as presumed EO (0.0079%). Positive cultures were documented in 2 of 3 cases. EO incidence following ranibizumab and conbercept administration was 0.0088% (3 in 33,930) and 0% (0 in 3,900), respectively. No significant difference was detected between the two drugs (P = 0.745). CONCLUSIONS: Very low EO rates were seen in mainland China using a standardized sterile technique in an OR. However, EO could not be completely avoided.
Authors: Andrew A Moshfeghi; Philip J Rosenfeld; Harry W Flynn; Stephen G Schwartz; Janet L Davis; Timothy G Murray; William E Smiddy; Audina M Berrocal; Sander R Dubovy; Wen-Hsiang Lee; Thomas A Albini; Geeta A Lalwani; Jaclyn L Kovach; Carmen A Puliafito Journal: Retina Date: 2011-04 Impact factor: 4.256
Authors: Nadim Rayess; Ehsan Rahimy; Philip Storey; Chirag P Shah; Jeremy D Wolfe; Eric Chen; Francis Char DeCroos; Sunir J Garg; Jason Hsu Journal: Am J Ophthalmol Date: 2016-03-02 Impact factor: 5.258
Authors: Philip Storey; Michael Dollin; John Pitcher; Sahitya Reddy; Joseph Vojtko; James Vander; Jason Hsu; Sunir J Garg Journal: Ophthalmology Date: 2013-10-18 Impact factor: 12.079
Authors: Suman Pilli; Athanasios Kotsolis; Richard F Spaide; Jason Slakter; K Bailey Freund; John Sorenson; James Klancnik; Michael Cooney Journal: Am J Ophthalmol Date: 2008-03-10 Impact factor: 5.258
Authors: Vincent Yeung; Nikolay Boychev; Wissam Farhat; Dimitrios P Ntentakis; Audrey E K Hutcheon; Amy E Ross; Joseph B Ciolino Journal: Int J Mol Sci Date: 2022-05-25 Impact factor: 6.208